Lorlatinib: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Lorlatinib. Educational only — not medical advice.

Labeled uses

LORBRENA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Source: FDA labeling via NIH DailyMed (set 2b34d62d…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.